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2Abstract
Background: Cognitive deficits persist despite clinical recovery in subjects with late 
life depression, but more needs to be known about their longer term outcome and 
factors affecting their course. To investigate this, we followed the pattern of cognitive 
impairments over time and examined the effects of current mood, remission status, 
age of depression onset and antidepressant treatment on these deficits.
Methods: Sixty-seven subjects aged 60 or over with DSM-IV major depressive 
disorder and 36 healthy comparison subjects underwent tests of global cognition, 
memory, executive functioning and processing speed at baseline, 6 and 18 months, 
with some subjects tested again after 4 years. Z-scores were compared between 
groups, with analyses of clinical factors which may have influenced cognitive 
performance in depressed subjects.
Results: Half of the patients exhibited a generalized cognitive impairment that 
persisted after 18 months (OR = 5.2, p = .011). Patients performed worse across all 
cognitive domains at all time points, without substantial variability due to current 
mood, remission status or antidepressant treatment. Late age of onset was 
significantly associated with decline in memory and executive functioning. Impaired 
processing speed may be a partial mediator of some deficits, but was insufficient to 
explain differences between patients and controls. Four year follow-up data suggest 
impairments persist, but do not further decline.
Conclusion: Cognitive deficits in late life depression persist up to 4 years, affect 
multiple domains and are related to trait rather than state effects. Differences in 
severity and course between early and late onset depression suggest different 
pathogenic processes.
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Cognitive deficits are a core feature of depression in adults of all ages, consistently 
found in the domains of memory, executive functioning and processing speed 
(Thomas and O'Brien, 2008). Previously such deficits were thought to be transient, in 
its most severe forms called ‘depressive pseudodementia’ (Bulbena and Berrios, 
1986), but mounting evidence shows cognitive deficits persist despite remission of 
depressive symptoms (Abas et al., 1990; Beats et al., 1996; Nebes et al., 2000;
Devanand et al., 2003; Portella et al., 2003; Adler et al., 2004; Neu et al., 2005;
Bhalla et al., 2006; Lee et al., 2007). These persisting deficits may be related to 
underlying neurobiological changes, including brain atrophy and an increased 
prevalence of white matter hyperintensities (Schweitzer et al., 2001; Herrmann et al., 
2008).
Although cognitive impairment is nowadays believed to be stable for the group of 
patients as a whole, recent studies have been short term (not exceeding 12 months) 
and longer term outcome has not been determined. There might also be differences 
between patients with specific clinical characteristics. For example, younger patients 
show a similar cognitive profile, but impairment is generally found to be more severe 
in older individuals (Gualtieri and Johnson, 2008; Thomas et al., 2008) and might be 
related to a late onset of depressive disorder (! 60 years) in particular (Herrmann et 
al., 2007). While modest improvement of cognition may occur in patients who were 
selected based on good response to antidepressant (AD) treatment (Butters et al., 
2000; Gallassi et al., 2006; Mandelli et al., 2006), it is largely unknown whether 
current AD treatment impacts on patients’ cognition compared to healthy subjects. 
Furthermore, controversy still remains as to whether cognitive impairment affects all 
cognitive domains or whether apparently multi-modal deficits in fact reflect a deficit in 
a single core neuropsychological function. Although the most suitable candidate, 
processing speed, has indeed been found to be a strong mediator of other cognitive 
deficits (Nebes et al., 2000; Butters et al., 2004), its effect might be greater for 
executive functioning than for episodic memory (Delaloye et al., 2008).
To address these questions we examined the pattern of cognitive deficits in healthy 
subjects and individuals with late-life major depression over time. We report 
differences between patients due to current symptom severity, remission status, age 
4of depression onset and antidepressant treatment. We hypothesized that i) current 
symptom severity would only marginally affect cognitive deficits, ii) remitted patients
would therefore show some amelioration of deficits but remain impaired, iii) later age 
of onset would be associated with more severe deficits without differences in the 
domains affected and iv) that those treated with antidepressants would not differ from
those not treated. In addition, we addressed the question whether processing speed 
mediates deficits in other cognitive domains.
Methods
Case ascertainment
Sixty-seven patients aged 60 and over who fulfilled DSM IV criteria for major 
depression were recruited from clinical old age psychiatry services covering 
geographically based catchment areas and included referrals from day hospitals, 
inpatient units and outpatient clinics. A control group (n=36) of similar aged older 
people (also all over 60 years of age) with no past history of depression or current 
depression were recruited from community sources such as The Royal British Legion 
and spouses of patients attending the same hospital units. The baseline 
neuropsychological profile of this group has been previously reported (O'Brien et al., 
2004). We excluded both subjects and controls with a history of prior cognitive 
impairment, history or evidence of stroke or transient ischemic attack, severe or 
unstable physical illness (e.g. insulin dependent diabetes mellitus, untreated 
hypothyroidism, uncontrolled heart failure, cancer) or a Cambridge Cognitive 
Examination (CAMCOG) (Roth et al., 1999) score of < 75 (patients) or < 80 
(controls). Additional exclusion criteria were: history or current substance/alcohol
abuse; long term use (> 2 months) of steroids during lifetime; use of steroid or other 
medication within the last 3 months thought to interfere with HPA axis; ECT in last 3 
months; use of medication thought to affect cognition (e.g. non-hypnotic 
benzodiazepines, antipsychotics or anticholinergic medication); presence of other 
neurological diagnosis. Use of newer antidepressants (e.g. SSRI’s and venlafaxine) 
and lithium was permitted, and only seven patients were taking tricyclic 
antidepressants (1 dothiepin, 6 lofepramine). The study was approved by the local 
ethics committee and all patients and controls gave written informed consent.
5Assessment
All depressed cases underwent a comprehensive psychiatric assessment including 
history, mental state, physical examination and a test of general cognitive functioning 
(CAMCOG). The CAMCOG is part of the Cambridge Mental Disorders of the Elderly 
Examination (CAMDEX) (Roth et al., 1999) and assesses general cognitive 
functioning and is frequently used in research and clinical practice.
Depression was diagnosed according to DSM-IV criteria (American Psychiatric 
Association) and symptom severity was rated using the MADRS (Montgomery and 
Asberg, 1979). In the present study, remission was defined as a MADRS score "#$#
(Hawley et al., 2002; Zimmerman et al., 2004). Demographic information (including 
past and current medical and psychiatric history, medication taken, family history, 
education and social class) and psychiatric history of past episodes of depression 
were collected from multiple sources to validate or enrich information from face-to-
face interviews with subjects and informants (e.g. case notes, GP records and 
informant accounts to determine number of previous episodes, age of onset and total 
lifetime duration of depression). An extensive neuropsychological test battery was 
administered to controls and all patients who consented to it.
Neuropsychological assessment
The test battery was primarily designed to measure memory, processing speed and 
executive function as they represent core neuropsychological deficits in late life  
depression (Thomas and O'Brien, 2008). Tests used in the present study included 
both traditional pen and paper and computerised tasks:
a) The Rey Auditory Verbal Learning Test (AVLT) (Rey, 1964), a test of episodic 
memory. The three measures immediate recall, delayed recall and delayed 
recognition (number of correct items) were used.
b) The FAS verbal fluency test (Lezak et al., 2004), a task sensitive to frontal 
lobe impairment. 
c) The Trail Making Test (TMT) (Lezak et al., 2004), a test of mental flexibility 
and divided attention.
d) The Stroop Colour Word Test (SCWT) (Stroop, 1935), a test for response 
inhibition and selective attention.
e) A computerised continuous performance task (VIGIL) (Cegalis and Bowlin, 
1991). Over 8 minutes, subjects have to press a button to a complex target 
6stimulus (letter K when preceded by the letter A), presented 100 times within a 
total of 480 stimuli (displayed serially in a pseudo-random fashion). Errors of 
omission and commission can be used as a measure of vigilance and 
inhibition but in the present study only response latencies (in msec) were used 
as a measure of processing speed.
Definition of generalized cognitive impairment (GCI)
There is no universally accepted definition of a suitable cut-off to denote significant 
cognitive impairment and 1, 1.5 and 2 standard deviations (SD) have all been used. 
In their definition of ageing associated cognitive decline Levy et al (1994) chose 1 
SD. The narrower, and more universally accepted, concept of mild cognitive 
impairment (Petersen et al., 1999) used 1.5 SD. consistent with this, we defined GCI 
as a score of more than 1.5 standard deviations below the healthy control groups’ 
mean on the CAMCOG at each assessment.
Follow-up
Patients and controls were re-assessed 6 and 18 months and again 4 years after 
baseline. At each time point, a psychiatric assessment, administration of rating 
scales and neuropsychological tests were repeated. At 6 months, 93 (90%) 
participants of the baseline sample were re-assessed and 78 (76%) at 18 months. At 
4 year, only 36 (35%) individuals, including 15 patients, were available for follow-up. 
Our analysis therefore focuses on the 6 and 18 months follow-up data but because 
longer term follow-up cognitive data on such patients is rarely available we have 
included the four year data too. While all patients had undergone clinical examination 
and CAMCOG testing at baseline, only 34 out of 67 of them were tested with the 
extended neuropsychological battery. While more could be tested at 6 (51 out of 57)  
and 18 (41 out of 45) months, this means that samples at different time points were 
not perfectly comparable. We thus decided to look at the associations cross-
sectionally only.
Statistical analysis
For ease of comparison, neuropsychological test scores were standardized using the 
control group’s mean and standard deviation at baseline. An overall memory z-score 
was created by adding up the three z-scores of the AVLT (immediate recall, delayed 
7recall, delayed recognition) and this ‘compound score’ was again standardized to a z-
score using the control group’s mean and standard deviation at baseline. Similarly, 
an overall executive functioning z-score was created by adding up the z-scores of 
verbal fluency, Trail Making Test difference A-B and SCWT correct responses. By 
this, we had three cognitive domains with higher scores indicating better 
performance: memory, executive functioning and processing speed (VIGIL latencies). 
The risk of having GCI at follow-up was assessed with logistic regression analyses 
yielding odds ratio’s (OR) and 95% confidence intervals (CI). We then used multiple 
linear regression analyses to test associations within cognitive domains. The impact 
of key clinical variables was investigated by comparing remitters and non-remitters, 
early onset and late onset, and AD users and non-users to healthy controls. In 
patients we also tested whether current MADRS scores (symptom severity), 
continuous age of onset and lifetime duration of AD intake predicted 
neuropsychological performance. All comparisons were adjusted for age, gender and 
years of education. The alpha-level for statistical significance was fixed at p "#%&%'&#
All tests were performed with STATA 9.2 (StataCorp, 2006).
Results
Descriptive analyses
Patients and their comparison subjects were well matched for age (p = .609) and 
gender (p = .633), but patients had higher MADRS scores (t = -12.2, df = 101, p < 
.001) and fewer years of formal education (t = 2.06, df = 101, p = .042) (Table 1).
<<< PLEASE INSERT TABLE 1 HERE >>>
Loss to follow-up
At 18 months, 22 (21%) participants were lost-to follow-up (LTFU), all within the 
patient group. Of these, 19 refused participation and 3 had died. Three control 
subjects had no data on CAMCOG or other neuropsychological testing. Among 
patients, being LTFU was not related to age (t = 0.10, df = 65, p = .919), gende(#)*+#,#
0.07, df = 65, p = .797), years of education (t = -0.27, df = 65, p = .785), ,age of onset 
(t = -0.04, df = 65, p = .972), MADRS score (baseline: t = -1.47, df = 65, p = .147; 6 
-./0123#0#,#%&456#78#,#''6#9#,#&:4$;6#(<-=22=./#20>0?2#)@>2<A=/<3#*+#, 0.53, df = 65, p = 
&5BBC#B#-./0123#*+#,#D&%56#78#,#''6#9#,#&4%E;6#@>2<A=/<#>/0=7<9(<22>/0#?2<#)*+#,#%&%56
8df = 65, p = .836) or weeks on medication (baseline: t = 0.10, df = 64, p = .919; 6 
months: t = 1.10, df = 43, p = .277). In addition, there were no significant differences 
between groups in total CAMCOG (baseline: t = 0.18, df = 64, p = .857; 6 months: t = 
1.74, df = 55, p = .087), memory (baseline: t = 1.12, df = 32,  p =.270; 6 months: t = 
1.11, df = 49, p = .274), executive functions (baseline: t = 1.19, df = 35, p = .241; 6 
months: t = 1.87, df = 49, p = .067) and processing speed (baseline: t = 0.83, df = 28, 
p = .414; 6 months: t = 0.72, df = 44, p = .478). However, all patients LTFU were on 
medication at 6 months follow up, resulting in a significant difference with patients not 
FGHI#)*+#,#5&%46#78#,#''6#9#,#&%5';&#
Depression and persistent generalized cognitive impairment (GCI)
One patient with missing CAMCOG scores was excluded from this analysis. Of the 
remaining 66 patients, 33 (50%) showed GCI defined as 1.5 standard deviations 
below the control group’s CAMCOG mean (Figure 1). Having GCI at baseline was 
highly predictive of having persistent GCI at 6 months (OR = 6.0, 95%CI = 
1.86;19.40, p = .003) and at 18 months (OR = 5.2, 95%CI = 1.41;19.18, p = .011). 
The risk increment remained robust after adjustment for age, gender, years of 
education, age of onset, remission status and current antidepressant use (6 months: 
OR = 5.85, 95%CI = 1.43;23.97, p = .014; 18 months: OR = 5.91, 95%CI = 
1.12;31.23, p = .036).
<<< PLEASE INSERT FIGURE 1 HERE >>>
Single-domain or multiple-domain cognitive impairment
Next, we wanted to test whether cognitive impairment is domain-specific or affects 
multiple cognitive domains. Separate linear regression analyses adjusted for age, 
gender and years of education showed that patients did significantly worse at all time 
points and in all domains (Table 2). Figure 2 illustrates this by showing little deviation 
from parallel running lines representing both groups’ unadjusted mean z-scores up to 
18 months.
<<< PLEASE INSERT TABLE 2 HERE >>>
<<< PLEASE INSERT FIGURE 2 HERE >>>
9Do deficits in processing speed drive the impairment in patients?
In order to test the mediating role of processing speed, analyses were repeated but
controlled for VIGIL latency z-scores. Adjusted for group, age, gender and education, 
processing speed was positively and significantly associated with memory (baseline: 
b = 0.31, 95%CI = 0.12;0.50, p = .002; 6 months: b = 0.43, 95%CI = 0.19;0.67, p =
.001; 18 months: b = 0.34, 95%CI = 0.08;0.60, p = .012) and executive functioning 
(baseline: b = 0.42, 0.19;0.65, p = .001; 6 months: b = 0.40, 95%CI = 0.13;0.68, p = 
.004; 18 months: b = 0.46, 95%CI = 0.23;0.70 p < .001). As can be seen in Table 2, 
adding processing speed to the regression model explained another 6-8% of the 
variance in memory scores. For executive functioning, this rose to 7-16%. Yet, 
differences between groups remained significant in both domains at all time points.
Stability of cognitive impairment: depression severity
Next, we tested whether cognitive impairments, despite being relatively stable for the 
group of patients as a whole, showed some variability due to differential associations 
with a number of a priori identified clinical factors. In order to test the influence of 
symptom severity in patients, we tested whether MADRS scores at the relevant 
follow-up point predicted cognition and found that they did not: memory (baseline: b = 
0.02, 95%CI = -0.06;0.11, p = .587; 6 months: b = -0.01, 95%CI = -0.05;0.03, p = 
.593; 18 months: b = -0.02, 95%CI = -0.06;0.03, p = .415), executive functioning 
(baseline: b = 0.01, 95%CI = -0.08;0.10, p = .814; 6 months: b = -0.00, 95%CI = -
0.04;0.04, p = .870; 18 months: b = -0.02, 95%CI = -0.07;0.03, p = .444), processing 
speed (baseline: b = 0.08, 95%CI = -0.03;0.18, p = .153; 6 months: b = -0.02, 95%CI 
= -0.06;0.01, p = .179; 18 months: b = -0.02, 95%CI = -0.06;0.02, p = .366).
Stability of cognitive impairment: remitted versus persistently depressed patients
Whether remission of depression went together with an amelioration of cognitive 
deficits was analysed in a sub-sample from which patients already in remission at 
baseline (MADRS < 10, n = 9) had been removed. At 6 months, 21 out of 48 (44%) 
available formerly depressed subjects were in remission, with another 14 out of 38 
(37%) available patients in remission at 18 months. At both follow-ups, remitting 
patients performed closer to healthy controls than depressed patients but both 
groups were still considerably impaired in memory and executive functioning (Table 
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3). For processing speed, both groups showed impairment at 6 months, but no 
significant difference with healthy controls at the 18 months follow-up.
Stability of cognitive impairment: early versus late onset depression
When defined on a continuous scale, age of onset was not significantly associated 
with executive functioning (baseline: b = 0.00, 95%CI = -0.03;0.03, p = .915; 6 
months: b = -0.01, 95%CI = -0.03;0.01, p = .423; 18 months: b = -0.02, 95%CI = -
0.05;0.01, p = .226) or processing speed (baseline: b = 0.02, 95%CI = -0.01;0.05, p = 
.227; 6 months: b = -0.00, 95%CI = -0.02;0.02, p = .955; 18 months: b = 0.00, 95%CI 
= -0.02;0.03, p = .796), but increasing age of onset was negatively related to episodic 
memory (baseline: b = -0.03, 95%CI = -0.06;-0.00, p = .049; 6 months: b = -0.03, 
95%CI = -0.05;-0.01, p = .010; 18 months: b = -0.03, 95%CI = -0.05;-0.00, p = .043). 
Thirty (45%) had an onset before age 60 (early onset depression, EOD) and 37 
(55%) thereafter (late onset depression, LOD). Both groups were impaired relative to 
controls at all time points in memory and executive functioning and at baseline and 6 
months testing of processing speed, but processing speed was not significantly 
impaired in either onset group at the 18 months follow-up (Table 3). Mean z-score 
differences with controls (as displayed in Table 3) suggest some improvement in 
EOD for all domains, while LOD showed signs of deterioration in memory and 
executive functioning relative to controls. Paired t-tests on the longitudinal 
association between 6 and 18 months cognition confirmed this by showing improved 
memory scores in controls (t = -3.24, df = 31, p = .003) and EOD (t = -2.63, df = 18, p 
= .017), but not LOD (t = -1.50, df = 19, p = .150) and stable executive functioning 
scores in controls (t = 0.22, df = 31, p = .828) and EOD (t = -1.70, df = 18, p = .106), 
yet decline in LOD (t = 2.33, df = 19, p = .031).
Stability of cognitive impairment: influence of antidepressant use
Both the acute effects of current AD use at time of testing (yes, no) and possible
long-term effects due to (cumulative) lifetime duration of AD intake (in weeks) were 
analysed. Duration of lifetime AD intake was not significantly associated with memory 
(b = 0.001, 95%CI = -0.001;0.004, p = .299; 6 months: b = 0.001, 95%CI = -
0.002;0.003, p = .486; 18 months: b = 0.001, 95%CI = -0.002;0.003, p = .533), 
executive functioning (b = 0.000, 95%CI = -0.003;0.003, p = .942; 6 months: b = -
0.002, 95%CI = -0.003;0.002, p = .863; 18 months: b = 0.002, 95%CI = -0.001;0.007, 
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p = .178) or processing speed (b = -0.001, 95%CI = -0.004;0.002, p = .503; 6 
months: b = 0.001, 95%CI = -0.001;0.003, p = .247; 18 months: b = 0.000, 95%CI = -
0.002;0.002, p = .958). At baseline, 57 (85%) patients were on medication. Of those 
available at follow-up, 46 (81%) were on AD at 6 months while 11 (19%) were not, 
and 34 (79%) were on AD at 18 months while 9 (21%) were not. Both, current AD 
users and non-user, displayed significant memory impairment at all time points and 
impaired executive functioning and processing speed at baseline and 6 months 
(Table 3). Overall, non-users had lower mean z-scores in all domains at baseline and 
6 months, yet at 18 months, they did not differ significantly from controls in executive 
functioning and processing speed.
<<< PLEASE INSERT TABLE 3 HERE >>>
Exploratory analyses of 4 year follow-up data
LTFU from baseline to 4 year follow-up was high with 67 (65%) of baseline 
participants dropping out of the study (52 (78%) patients, 15 (41%) of controls). 
Reasons for LTFU were refusal (n = 41, 61%), death (n = 10, 15%), being too late for 
follow-up (n = 6, 9%), physical health (n = 6, 9%), and other (n = 4, 6%). One patient 
had developed possible dementia. Being LTFU at 4 years was independent of age (t 
= -1.41, df = 101, p = .160), gender (*+#,#J&J:6#78#,#D%D6#p = .132), remission status at 
18 months (*+#,#%&E46#78#,#546#p = .362) and baseline executive functioning (p = .112) 
and processing speed scores (p = .589), but was significantly associated with fewer 
years of education (t = -2.06, df = 101, p = .042) and worse baseline episodic 
memory (t = -2.72, df = 68, p = .008). In addition, patients with a later onset (t = -2.53, 
df = 65, p = .014) were more likely to be LTFU. Taken together, this pattern reflects 
the higher attrition in the patient group as opposed to controls.
Of the 15 patients followed-up, 6 had a GCI at baseline and 3 of them had persistent 
GCI after 4 years, but statistical testing failed to reach significance (OR = 8.0, 95%CI 
= 0.58;110.27, p = .120). A rather wide 95% confidence interval indicated that this 
was probably due to small sample size, and it is notable that the OR was similar in 
magnitude to that found at 6 and 18 months. Regarding domain specific impairment, 
t-tests suggest a pattern that is consistent with the 6 and 18 months follow-up, but 
tests lacked power and were therefore not always conclusive. Thus, patients’ 
impairment seemed to persist relative to controls in executive functioning (t = 3.00, df 
12
= 34, p = .005), and processing speed (t = 2.36, df = 29, p = .025), with a trend into 
the same direction for episodic memory (t = 1.90, df = 34, p = .065).
Discussion
Main findings
We found that cognitive impairment in depressed subjects persists in many subjects, 
affects multiple cognitive domains and is not significantly influenced by illness factors 
such as current mood, remission status or current antidepressant (AD) use. 
Persistence was only partially explained by information processing speed. Patients 
with a later age of onset displayed worse episodic memory functioning.
The 18 months findings augment earlier reports of shorter follow-up duration (Adler et 
al., 2004; Bhalla et al., 2006; Lee et al., 2007) and studies in younger cohorts 
(Weiland-Fiedler et al., 2004; Airaksinen et al., 2006; Reppermund et al., 2007) 
showing that cognitive deficits are highly persistent in depressive disorder. 
Furthermore our findings show that incident cognitive impairment can develop in 
people with prevalent depression while (some) amelioration of deficits occurs in 
some individuals with initial deficits. Yet, the most common outcome is that of no 
change at all: persistent impairment or persistent absence of it.
State or trait effects?
Patients’ impairments in single cognitive domains were independent of current 
symptom severity and not related to state effects such as current mood. Likewise, 
remitting patients showed similar cognitive impairments as depressed patients, albeit 
milder. Persistent deficits have been reported frequently (Abas et al., 1990; Beats et 
al., 1996; Nebes et al., 2000; Devanand et al., 2003; Portella et al., 2003; Adler et al.,
2004; Neu et al., 2005; Bhalla et al., 2006; Lee et al., 2007) and are a core feature of 
the disorder itself. We found mixed results for the influence of AD treatment on 
cognition, but overall, there were only small differences between those who were and 
were not on medication. If anything, patients taking AD’s performed slightly better in 
all cognitive domains at baseline and 6 months, which does not imply that medication 
affected cognition negatively in this sample. Inconsistent with this was that those who 
did not take AD’s did not differ from controls at 18 months follow-up testing of 
executive functioning and processing speed. While at least for executive functioning 
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this might have been due to lack of power (the mean score of the eight patients 
tested and currently not on AD was still one standard deviation below controls), the 
lack of a consistent effect of AD treatment can be seen as evidence that it was not a 
major factor mediating cognitive deficits in our sample. In addition, lifetime 
antidepressant treatment had no major effects on cognitive functioning at any time 
point. Taken together, these findings imply a trait effect on neurocognition, most 
probably caused by structural cerebral changes which have been consistently 
reported in depression, especially LOD (Schweitzer et al., 2001, Herrmann et al., 
2008).
The role of processing speed
Consistent with the literature, impairment was found to affect multiple cognitive 
domains, including episodic memory, executive functioning and processing speed 
(Thomas and O'Brien, 2008). Like in earlier reports, deficient processing speed made 
major contributions to cognitive deficits in other domains (Nebes et al., 2000; Butters 
et al., 2004). In the present study however, its effect on executive functioning deficits 
was greater than on memory deficits, confirming one earlier report (Delaloye et al., 
2008). However, it was insufficient to fully explain differences between patients and 
controls, indicating other deficits exist in parallel. These may stem from structural 
brain changes, including hippocampal atrophy (Sapolsky, 2000; Steffens et al., 2000;
O'Brien et al., 2004; Hickie et al., 2005), frontal lobe atrophy/volume reduction 
(Schweitzer et al., 2001; Almeida et al., 2003; Lavretsky et al., 2004) and (mainly 
frontal) deep white matter lesions (Herrmann et al., 2008), which, in their diversity, do 
not suggest single-domain impairment.
Biological explanations for cognitive impairment in late life depression
Current explanations of potential mechanisms for these brain changes focus on 
cerebrovascular pathology (Alexopoulos et al., 1997) and glucocorticoid action 
(Sapolsky et al., 1986). The “vascular hypothesis” (Alexopoulos, 2006) is based on 
the consistent finding of white matter hyperintensities (Herrmann et al., 2008), 
especially in the form of ischemic lesions (Thomas et al., 2002). In normal ageing 
(Turken et al., 2008) and multiple sclerosis (Amato et al., 2008) such lesions are 
associated with reduced processing speed, but have also been related to executive 
functioning deficits in late life depression (Sheline et al., 2008). The “glucocorticoid 
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cascade hypothesis”, based on animal models (O'Brien, 1997; Sapolsky, 2000;
McEwen, 2005), proposes the dysregulation of the hypothalamic-pituitary-adrenal 
axis leads to brain atrophy but direct evidence in humans has been inconsistent 
(O'Brien et al., 2004).
Age of onset of depression
Apparently incompatible with the glucocorticoid cascade hypothesis, subjects with an 
early onset (and thus a longer illness duration) did not display greater memory 
deficits or increasing memory deficits over time, which may point to different 
pathogenic pathways between both onset groups. LOD is more strongly related to 
cerebrovascular changes than EOD (Schweitzer et al., 2001; Herrmann et al., 2008), 
and they demonstrate greater hippocampal volume reduction (Lloyd et al., 2004;
Hickie et al., 2005). These changes might be superimposed on any 
pathophysiological changes that are shared with EOD (e.g. glucocorticoid action) and 
so explain the greater cognitive deficits seen in LOD.
Long term course of late life depression
During the medium-term course (baseline to 18 months), we found little evidence of 
further progression of deficits. Patients’ change in test scores paralleled that seen in 
controls, which implies that both profited equally from learning effects and increasing 
task familiarity. Patients with late onset depression tended to show worsening of 
memory and executive functioning relative to controls, either due to absence of 
improvement or true decline, which  was not observed in early onset patients. The 
exploratory analyses of the four year data suggest patients remain impaired long-
term, but again without evidence of further decline and only one patient developed 
dementia during the study. As patients with more severe impairment tended to drop 
out of the study, this might however give a too favorable picture of the true course. 
Methodological considerations
The present study has several strengths including an age and gender matched 
healthy comparison group tested at the same time points, a relatively long follow-up
duration and the administration of a comprehensive neuropsychological test battery 
tapping into core cognitive domains. However, some methodological shortcomings 
have also to be considered. First, this study was observational. Hence we did not
15
manipulate antidepressant regime. Other studies found improvement of cognition 
with AD use, mainly in subgroups of good responding patients (Butters et al., 2000;
Gallassi et al., 2006; Mandelli et al., 2006). Cognitive functioning might therefore still 
be a suitable target for AD treatment, especially since they displayed somewhat 
better cognitive functioning in the present study, too, although staying impaired. 
Second, more subjects could be tested with the extended neuropsychological test 
battery at follow-up than at baseline, and thus groups at different time points are not 
perfectly comparable. Therefore we focussed primarily on the cross-sectional 
analyses and tested longitudinal changes between age of onset groups only from 6 
to 18 months yet not from baseline. In addition, in contrast to some other reports, we
did not control for estimated IQ, but instead used years of education to adjust for 
premorbid level of functioning. Lost-to follow-up at 18 months among patients was 
within normal range and unrelated to differences in variables of interest to the 
present study, with the exception of a higher dropout among antidepressant users. 
Still, 75% of those seen at 18 months were on medication and it therefore seems 
unlikely that bias occurred due to selective drop-out. However, coefficients suggest 
that loss-to follow-up was preceded by worse cognition at previous assessments. 
This would explain the apparent convergence of patients and controls at the 18 
months assessment (see Table 2). Finally, we reported the four year data because of 
the paucity of longer term studies in the literature, but at this point we observed high 
and seemingly non-random drop-out among patients, so we advise to interpret these 
results with due caution. Further studies of comparable follow-up length (and beyond) 
are clearly needed to verify these findings. 
Conclusion
The present study shows that cognitive deficits in late life depression tend to persist 
up to at least 4 years without further deterioration, affect multiple domains and 
appear to be related to trait rather than state effects. Differences in the severity and 
course of cognitive deficits due to age of onset imply different pathogenic processes 
between early and late onset depression.
16
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TABLES AND FIGURES
Table 1. Baseline demographic characteristics for depressed and control subjects.
Patients Controls P
N = 67 N = 36
Age, years, mean(SD) 74.1(6.7) 73.4(6.9) ns
Gender, % female 53 (79) 27 (75) ns
Education, years, mean(SD) 9.6 (2.1) 10.5 (2.1) .042
MADRS, mean(SD) 23.6 (10.4) 2.2 (2.2) < .001
Age of onset, mean(range) 57.4 (17-85) - -
Illness duration, weeks, mean(range) 52.9 (2-268) - -
Episodes, n, mean(range) 3.1 (1-15) - -
In remission, n(%) 9 (13) - -
With melancholic features, n(%) 27 (47) - -
Severely depressed, DSM-IV, n(%) 22 (33) - -
With psychotic symptoms, n(%) 9 (16) - -
Antidepressants, n(%)
a
None 11 (16) - -
SSRI's 36 (54) - -
SNRI’s 12 (18) - -
Tricyclics 7 (10) - -
MAO inhibitors 3 (4) - -
Pre-baseline electroconvulsive treatment, n(%) 21 (31) - -
a Percentages do not add up to 100 because two depressed subjects were taking 
SSRI (citalopram) and tricyclic (one dothiepin, one lofepramine) antidepressant 
medication.
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Figure 1. Diagram showing numbers of depressed patients with and without 
generalized cognitive impairment (GCI) at each assessment. Arrows indicate how 
many patients were lost-to follow-up (LTFU), remained with or without GCI, or made 
transitions between GCI groups from baseline to follow up. The odds ratio (OR) and 
p-value for having GCI at follow-up given GCI at baseline is also shown.
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Table 2. Difference in mean z-scores of individual cognitive domains between 
depressed subjects and controls at baseline and follow-up.
Controls versus Depressed Adjusted for processing speed
Z-score diff. 95%CI R² Z-score diff. 95%CI R²
Episodic memory baseline -1.50*** -2.04;-0.97 0.44 -1.18*** -1.73;-0.62 0.52
6 months -1.46*** -2.03;-0.89 0.32 -0.86** -1.46;-0.25 0.40
18 months -1.41*** -2.05;-0.76 0.28 -1.09** -1.77;-0.42 0.34
Executive functioning baseline -1.40*** -2.00;-0.80 0.33 -0.85* -1.50;-0.19 0.42
6 months -1.48*** -2.04;-0.91 0.34 -0.90** -1.49;-0.32 0.41
18 months -1.15*** -1.83;-0.48 0.29 -0.67* -1.28;-0.06 0.45
Processing speed baseline -1.13*** -1.80;-0.46 0.17 - - -
6 months -1.09*** -1.59;-0.59 0.25 - - -
18 months -0.74* -1.38;-0.10 0.18 - - -
*** p " .001, ** p "#&%D6#K#9#"#&%'
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Figure 2. Plotted unadjusted z-score means illustrating cognitive trajectories over 
time for control and depressed subjects in individual cognitive domains.
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